Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Stereotactic body radiation therapy (SBRT) is a very precise form of radiation therapy that
allows the physician to deliver more radiation dose in a single session. Because of this, the
number of radiation sessions can be reduced from the typical 45-48 sessions, as in
conventional daily session radiation, to 5 sessions given every other day over a week and a
half. Giving the radiation at a higher dose during each treatment may be more effective in
killing the prostate cancer cells than the standard way of using external radiation therapy
where a small amount of radiation is given over many sessions.
Androgen Deprivation Therapy (ADT) or hormonal therapy is one of the methods to treat
intermediate risk prostate cancer. This therapy works by reducing the level of testosterone
and stopping them from affecting your cancer. The ADT used in this study is known as
Degarelix. Degarelix is an approved medication that reduces the body's production of
testosterone; this medication is usually given to all men with intermediate risk prostate
cancer getting external radiation.
This study is a randomized study to find out whether combining stereotactic (also known as
precision) radiation to the prostate cancer combined with a short course of Degarelix will
result in a greater likelihood of killing the cancer in the prostate compared to stereotactic
radiation therapy given alone. It has been shown that the combination of radiation with
medications that interfere with testosterone production and its effects makes prostate cancer
cells more sensitive to the radiation.
Phase:
Phase 3
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Ferring Pharmaceuticals University of Michigan University of Texas Southwestern Medical Center